ProQR Therapeutics N.V

Company snapshot

Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary Axiomer™ RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacan

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 19 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ProQR Therapeutics N.V. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ProQR Therapeutics N.V.

1. Jun 8, 2026 Clinical update

   PQ-0810-001 — Phase 1

2. Jun 5, 2026 Clinical update

   QR-504a — Phase 1

3. Jun 5, 2026 Clinical update

   QR-1123 — Phase 2

4. May 23, 2026 Clinical update

   sepofarsen — Phase 3

5. May 23, 2026 Clinical update

   QR-010 — Phase 2

View all clinical trial activity →

• What is ProQR Therapeutics N.V?

  ProQR Therapeutics is a pharma organization headquartered in Leiden, NL. It trades on NYSE under ticker PRQR. Primary therapeutic focus areas include Cholestatic liver disease, Cystic Fibrosis, Autosomal Dominant Retinitis Pigmentosa, Retinitis Pigmentosa, Fuchs Endothelial Corne

• Is ProQR Therapeutics N.V publicly traded?

  Yes. ProQR Therapeutics N.V is listed with ticker PRQR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ProQR Therapeutics N.V develop or market?

  We link 2 drug profile(s) where ProQR Therapeutics N.V is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/proqr-therapeutics-n-v#company-drugs.

• What are the latest developments for ProQR Therapeutics N.V?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ProQR Therapeutics N.V focus on?

  ProQR Therapeutics N.V focuses on Cholestatic liver disease, Cystic Fibrosis, Autosomal Dominant Retinitis Pigmentosa based on our analysis of their pipeline programs and drug development activities.